Fang Weigang, Zeng Xuejun, Li Mengtao, Chen Lan X, Schumacher H Ralph, Zhang Fengchun
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
J Rheumatol. 2006 Oct;33(10):2041-9.
Gout is a less commonly diagnosed rheumatic disease in China compared with Western countries, but its prevalence appears to be climbing. It is not known how Chinese physicians diagnose and treat their patients with gout, so we evaluated physician management of gout at a major academic healthcare center in Beijing, and investigated factors associated with better decision-making.
A 13-question anonymous survey was distributed and collected at a medical grand rounds and then at a rheumatology grand rounds at a major teaching hospital in Beijing. Physician demographic data including educational background, work experience, job titles, specialty or subspecialties, gout patient volume seen in a year, and continuing medical education (CME) in gout were also collected in the survey. Data were analyzed by multivariate regression models to identify factors associated with appropriate answers.
Twenty-seven residents and general internists, 26 rheumatologists and fellows, and 28 physicians and fellows of other medical subspecialties from the Department of Medicine including visiting physicians responded to the survey. Among respondents, 78% think it is important for a definitive diagnosis of gout, but few actually perform aspiration of the affected joint fluid. Eighty-four percent report that they often follow the serum urate level of their patients with diagnosed gout. When treating acute gout in otherwise healthy patients, most physicians (77%) prefer oral colchicine, and in patients with renal impairment, about half of them (48%) choose corticosteroids or corticotropin as their first treatment. For longterm urate-lowering therapy, most physicians (87%) described a variety of indications that we consider less appropriate. They (86%) tend to initiate it early (< 2 weeks) after acute flares. When urate-lowering therapy is used, 80% of physicians sustain it less than 5 years. Further, only 12% of physicians use antiinflammatory prophylaxis during the initiation of urate-lowering treatment, and only 5% maintain it for an appropriate period of time. Logistic regression analysis of physician demographic data, educational background, and work experience found no consistent independent factors associated with better decision-making, other than CME, that were associated with establishing the definite diagnosis correctly. Specifically, the number of gout patients seen by physicians was not related to better decision-making.
The physicians' reported management of gout at this major academic healthcare center in Beijing was often inconsistent with current evidence. High quality CME is required to improve Chinese physician management of gout.
与西方国家相比,痛风在中国是一种较少被诊断出的风湿性疾病,但其患病率似乎在攀升。目前尚不清楚中国医生如何诊断和治疗痛风患者,因此我们评估了北京一家主要学术医疗中心医生对痛风的管理情况,并调查了与更好决策相关的因素。
在北京一家主要教学医院的医学大查房和随后的风湿病大查房期间分发并收集了一份包含13个问题的匿名调查问卷。调查问卷还收集了医生的人口统计学数据,包括教育背景、工作经验、职称、专业或亚专业、一年中诊治的痛风患者数量以及痛风方面的继续医学教育(CME)情况。通过多变量回归模型对数据进行分析,以确定与正确答案相关的因素。
来自医学部的27名住院医师和普通内科医生、26名风湿病学家和进修医生以及28名包括客座医生在内的其他医学亚专业的医生和进修医生对调查做出了回应。在受访者中,78%的人认为明确诊断痛风很重要,但实际进行受累关节液抽吸的人很少。84%的人报告说他们经常跟踪已确诊痛风患者的血清尿酸水平。在治疗其他方面健康的急性痛风患者时,大多数医生(77%)更喜欢口服秋水仙碱,而在肾功能损害患者中,约一半(48%)的医生选择皮质类固醇或促肾上腺皮质激素作为首选治疗方法。对于长期降尿酸治疗,大多数医生(87%)描述了各种我们认为不太合适的适应症。他们(86%)倾向于在急性发作后早期(<2周)开始治疗。在使用降尿酸治疗时,80%的医生维持治疗时间不到5年。此外,只有12%的医生在开始降尿酸治疗期间使用抗炎预防措施,只有5%的医生维持适当的时间。对医生人口统计学数据、教育背景和工作经验进行逻辑回归分析发现,除了CME与正确建立明确诊断相关外,没有一致的独立因素与更好的决策相关。具体而言,医生诊治的痛风患者数量与更好的决策无关。
北京这家主要学术医疗中心的医生报告的痛风管理情况往往与当前证据不一致。需要高质量的CME来改善中国医生对痛风的管理。